Biogen (NASDAQ: BIIB) reported profit for the fourth quarter that declined but easily topped expectations as its sales of treatments for multiple sclerosis surged. Sales of its treatment Tecfidera jumped by 8.4% to over $993 million as sales of other treatments it has for multiple sclerosis dropped. The profit at the biotechnology company fell by […]